PCSK9抑制剂在动脉粥样硬化性心血管疾病中的抗炎作用研究进展

Research progress in the anti-inflammatory effect of PCSK9 inhibitors in atherosclerotic cardiovascular disease

高脂血症是动脉粥样硬化性心血管疾病(ASCVD)的重要危险因素,降脂治疗是ASCVD治疗的重要内容。近些年来,前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin/kexintype9,PCSK9)抑制剂被证实具有强效的降低低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)的作用,并被多个降脂指南推荐作为降脂治疗的重要方法。随着研究的深入,PCSK9抑制剂除具有降低LDL-C作用外,还发挥一定程度的抗炎作用。本文从PCSK9参与炎症反应角度出发,对PCSK9抑制剂在ASCVD中的抗炎作用作一综述。

Hyperlipidemia is an important risk factor for atherosclerotic cardiovascular disease(ASCVD),and lipid-lowering therapy is an important part of ASCVD treatment.In recent years,PCSK9 inhibitors,proven to have potent LDL-C lowering effects,have been recommended by several guidelines as an important method for lipid-lowering therapy.With the deepening of research,PCSK9 inhibitors not only have the effect of lowering LDL-C,but also play a certain degree of anti-inflammatory effect.This article reviews the anti-inflammatory effect of PCSK9 inhibitors in ASCVD from the perspective of the involvement of PCSK9 in inflammatory responses.